Mechanism of action and effect on lipids
The site of action of nicotinic acid is adipose tissue, specifically adipocytes. Normally, the enzyme TAG lipase (triacylglycerol lipase) breaks down triglycerides, releasing fatty acids into the bloodstream for delivery to the liver. Niacin inhibits this enzyme, triggering the following cascade of reactions:
- Lipolysis in adipocytes is reduced.
- The formation of free fatty acids (FFAs) and their transport to the liver are decreased.
- Substrate deficiency occurs in the liver, leading to a drop in triglyceride (TG) biosynthesis.
- As a result, the formation and secretion of atherogenic very-low-density lipoproteins (VLDL) are reduced.
As a result of therapy, the blood lipid profile changes dramatically. The drug reduces the levels of VLDL, intermediate-density lipoproteins (IDL), and low-density lipoproteins (LDL). At theConversely, the level of anti-atherogenic high-density lipoproteins (HDL) increases.
Pharmacokinetics and Clinical Application
The drug is rapidly and completely absorbed from the gastrointestinal tract, with a bioavailability of about 72%. Metabolism occurs in the liver, and excretion is carried out by the kidneys (primarily as metabolites). The half-life is very short, at only 45 minutes. Extended-release forms of the drug also exist (e.g., Enduracin).
Despite its rapid pharmacokinetics, the maximum lipid-lowering effect develops slowly — taking about two months of continuous therapy. After drug withdrawal, the beneficial aftereffect persists for 2 to 6 weeks.
Clinically, niacin is used for hyperlipoproteinemias types IIa, IIb, III, IV, and V. The highest efficacy is recorded in types III and V. It is important to understand the colossal difference in dosages: while the daily vitamin requirement is only about 16 mg, the therapeutic lipid-lowering dose reaches 1.5–3 g per day (hundreds of times higher).
Side effects and combination therapy
The main problem with high doses is pronounced adverse reactions: flushing (redness) of the face, neck, and upper chest, skin itching, as well as gastrointestinal and cardiovascular disorders.
These symptoms occur because nicotinic acid stimulates increased synthesis of prostaglandins (specifically D2 and E2). Prostaglandin D2 activates DP1 receptors in skin blood vessels, causing them to dilate. Important: this process is not related to the lipid-lowering effect — there is no causal relationship between lipid reduction and prostaglandin release.
Two approaches are used to prevent "flushes":
- Taking acetylsalicylic acid 30 minutes before niacin (to inhibit prostaglandin synthesis).
- Using prostaglandin receptor blockers, such as laropiprant.
Laropiprant is a selective DP1 receptor antagonist. It is rapidly absorbed (71% bioavailability), metabolized via glucuronidation, and excreted through the intestine as a glucuronide. The half-life is about 17 hours. In modern practice, a combination drug (e.g., Tredaptive) is used, containing 1000 mg of nicotinic acid and 20 mg of laropiprant. This allows the use of high therapeutic doses of niacin with a minimal risk of skin reactions.
Briefly: answers to topical questions
What systemic side effects (aside from skin reactions) are caused by high doses of nicotinic acid?
High doses of nicotinic acid cause systemic side effects in the form of gastrointestinal (GI) and cardiovascular disorders. Systemic manifestations also include pronounced vasodilation (blood vessel dilation) both peripherally and in the brain. These adverse events complement the characteristic skin reactions (flushing of the face, neck, upper chest, and skin itching) that develop due to the stimulation of prostaglandin synthesis.
To remember the niacin cascade, use the "Three Rs" rule: Reduction of lipolysis in adipose tissue → Reduction of triglyceride synthesis in the liver → Reduction of VLDL in the blood.
Class and exam questions
Why does nicotinic acid cause facial flushing and itching?
The drug stimulates the synthesis of prostaglandin D2, which activates specific receptors in skin blood vessels, causing their sharp dilation and blood inflow.
Is prostaglandin release linked to the lipid-lowering effect?
No, these are two parallel processes. The reduction in lipid levels and the synthesis of prostaglandins have no causal relationship.
How to prevent skin reactions when taking niacin?
Taking acetylsalicylic acid 30 minutes before niacin or using combination drugs with receptor blockers (e.g., with laropiprant) is recommended.
What else to study on this topic
- The biochemical role of TAG lipase normally and during niacin inhibition.
- Classification of hyperlipoproteinemias (types IIa, IIb, III, IV, V) and therapy selection.
- Pharmacokinetics and metabolism of laropiprant (the glucuronidation process).
- Interaction of nicotinic acid with prostaglandin synthesis inhibitors.
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Nicotinic acid" and 5,304 other subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Drugs used in atherosclerosis"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.